Latest California Healthline Stories
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
The nation’s second-largest insurer is shrinking its presence on Obamacare exchanges and in the broader individual market in response to prevailing uncertainty. California is just the latest — and the biggest — example.
A new study suggests 13 percent of two-year college students can’t consistently get access to or afford enough food.
The figure could be higher if President Trump ends an important consumer subsidy, which he has threatened to do. Anthem Blue Cross will pull out of the exchange and the overall individual market in 16 of 19 regions in the state.
Health care journalists in Washington, D.C., discuss the next round of national health reform — assuming there is one.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Kaiser Health News examines the role of PBMs in the prescription drug-pricing pipeline.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Aunque se han promovido directrices anticipadas durante casi 50 años, sólo un tercio de los adultos estadounidenses las prepara, revela un estudio reciente.
By taking aim at the subsidies received by some congressional staff members who, under the Affordable Care Act, are mandated to get their health coverage from the Obamacare exchanges, the president reignited an old fight.